RXRXHealthcare · BiotechnologyThe 7 Wall Street analysts covering Recursion Pharmaceuticals, Inc. hold a median 12-month price target of $7 — +81.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Recursion Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Volatility (36): The share price moves around a lot.
Size (33): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RXRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +81.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | Needham | Reiterates | Buy | $8.00 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $5.00 → $5.50 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 May 2026 | Needham | Reiterates | Buy | $8.00 |
| 7 May 2026 | Needham | Reiterates | Buy | — |
| 30 Apr 2026 | JP Morgan | Maintains | Overweight | — |
| 26 Feb 2026 | B of A Securities | Maintains | Neutral | — |
| 26 Feb 2026 | Needham | Reiterates | Buy | — |
| 17 Dec 2025 | JP Morgan | Upgrade | Overweight | — |
| 11 Sept 2025 | Needham | Reiterates | Buy | — |
| 8 July 2025 | Needham | Reiterates | Buy | — |
| 3 July 2025 | Morgan Stanley | Assumes | Equal-Weight | $5.00 |
| 16 June 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 May 2025 | Needham | Maintains | Buy | — |
| 10 Apr 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 28 Feb 2025 | Leerink Partners | Maintains | Market Perform | — |
| 6 Feb 2025 | Needham | Reiterates | Buy | — |
| 8 Jan 2025 | Keybanc | Maintains | Overweight | — |
| 11 Dec 2024 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RXRX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Recursion Pharmaceuticals, Inc. returned −22.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 6% of US stocks
Cheaper than 37% of US stocks
Cheaper than 80% of US stocks
Higher than 96% of US stocks
Higher than 8% of US stocks
Higher than 2% of US stocks
Higher than 7% of US stocks
Higher than 58% of US stocks
Higher than 22% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Recursion Pharmaceuticals, Inc. has a market value of $2.3B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $53.9M. The latest quarter grew 258.5% year on year.
Net income over the same four quarters: −$518.9M, a −962.0% net margin.
Diluted earnings per share, trailing twelve months: $−1.04.
Free cash flow in the twelve months to 30 June 2026: −$354.3M.
Trailing P/E: −2.7×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Recursion Pharmaceuticals, Inc. employs 600 people — $90K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Recursion Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Recursion reported promising clinical data for REC-4881 and REC-1245, beat Q3 earnings estimates, and said disciplined spending extends its cash runway into 2029.
Why it matters — The update highlights clinical progress and the company’s reported financial runway.
Recursion Pharmaceuticals held its Q3 2026 earnings call on November 3, 2026, with CEO Najat Khan, Chief Medical Officer Vicki Goodman, and CFO Ben Taylor among the company participants. The excerpt contains the call opening but no details on results or business updates.
Why it matters — RXRX watchers may note the timing and participants, though the provided excerpt does not disclose substantive company developments.
Recursion Pharmaceuticals reported updated clinical data for its investigational FAP treatment, early activity in its solid-tumor program REC-1245, partnership progress, and an expected cash runway extending into 2029.
Why it matters — The update covers clinical programs, partnerships, and the company’s expected funding runway—key areas RXRX watchers may monitor.
Recursion Pharmaceuticals reported Q3 revenue up 258.5%, beating estimates, with results boosted by a $10 million Sanofi milestone payment. The payment also advances its drug pipeline.
Why it matters — The report highlights the contribution of a Sanofi milestone payment to RXRX's quarterly revenue and pipeline progress.
Recursion Pharmaceuticals reported a Q3 loss of $0.22 per share, compared with the Zacks consensus estimate of a $0.24 loss and a $0.36 loss per share a year earlier. The headline also says the company topped revenue estimates.
Why it matters — RXRX watchers may note the smaller-than-expected quarterly loss and the year-over-year change in per-share loss.
The 7 Wall Street analysts covering Recursion Pharmaceuticals, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Recursion Pharmaceuticals, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Recursion Pharmaceuticals, Inc. 61 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Recursion Pharmaceuticals, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +81.1% from the last close, and Ticker Nerd's factor model ranks Recursion Pharmaceuticals, Inc. 61 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Recursion Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
Recursion Pharmaceuticals, Inc. returned -22.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Recursion Pharmaceuticals, Inc. Class A Common Stock represents ownership in Recursion Pharmaceuticals, a clinical-stage TechBio company focused on industrializing drug discovery through data-driven biology and chemistry.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway". Recursion reported promising clinical data for REC-4881 and REC-1245, beat Q3 earnings estimates, and said disciplined spending extends its cash runway into 2029.
Recursion Pharmaceuticals, Inc. Class A Common Stock represents ownership in Recursion Pharmaceuticals, a clinical-stage TechBio company focused on industrializing drug discovery through data-driven biology and chemistry. The company uses automation, artificial intelligence, machine learning, and engineering to map biological systems and identify novel therapeutic candidates. Its work centers on building a technology-enabled platform for discovering and advancing medicines across areas such as oncology, rare disease, and other complex conditions. Recursion also operates in a research and development environment that combines wet-lab biology with computational tools to improve the efficiency of early-stage drug discovery. Headquartered in Salt Lake City, Utah, Recursion Pharmaceuticals plays a specialized role in the biotechnology market as a developer of platform-based drug discovery capabilities and clinical-stage therapeutic programs.
CEO Dr. Najat Khan Ph.D. · 600 employees · United States · https://www.recursion.com
